July 1 (Reuters) - Cue Biopharma Inc CUE.O:
CUE BIOPHARMA PROVIDES UPDATE ON MOST ADVANCED CLINICAL STAGE ASSET, CUE-101, PRESENTED BY DR. DIMITRIOS COLEVAS AT THE DAVA 4TH HAWAII GLOBAL SUMMIT ON THORACIC MALIGNANCIES
CUE BIOPHARMA INC - ORR OF 50% IN HPV+ R/M HNSCC PATIENTS
CUE BIOPHARMA INC - 12-MONTH SURVIVAL OF 88% AND MOS OF 32 MONTHS
Source text: ID:nGNX9PRPqp
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.